AAPL   318.18 (+0.15%)
AMZN   1,884.73 (-0.15%)
AMD   51.26 (-0.33%)
F   9.14 (-0.22%)
PRI   125.51 (-0.91%)
DIS   143.44 (-0.40%)
AAPL   318.18 (+0.15%)
AMZN   1,884.73 (-0.15%)
AMD   51.26 (-0.33%)
F   9.14 (-0.22%)
PRI   125.51 (-0.91%)
DIS   143.44 (-0.40%)
AAPL   318.18 (+0.15%)
AMZN   1,884.73 (-0.15%)
AMD   51.26 (-0.33%)
F   9.14 (-0.22%)
PRI   125.51 (-0.91%)
DIS   143.44 (-0.40%)
AAPL   318.18 (+0.15%)
AMZN   1,884.73 (-0.15%)
AMD   51.26 (-0.33%)
F   9.14 (-0.22%)
PRI   125.51 (-0.91%)
DIS   143.44 (-0.40%)
Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:RDNT - RadNet Stock Price, Forecast & News

$21.40
+0.28 (+1.33 %)
(As of 01/23/2020 09:19 AM ET)
Today's Range
$21.19
Now: $21.41
$21.55
50-Day Range
$18.73
MA: $19.98
$21.41
52-Week Range
$10.69
Now: $21.41
$21.55
Volume241,644 shs
Average Volume229,316 shs
Market Capitalization$1.08 billion
P/E Ratio31.95
Dividend YieldN/A
Beta0.97
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$975.15 million
Cash Flow$2.26 per share
Book Value$4.10 per share

Profitability

Net Income$32.24 million

Miscellaneous

Employees7,869
Market Cap$1.08 billion
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) announced its quarterly earnings results on Tuesday, November, 12th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.05. The medical research company earned $292.70 million during the quarter, compared to the consensus estimate of $283.39 million. RadNet had a return on equity of 16.52% and a net margin of 3.02%. The firm's revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for RadNet.

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$1.1-1.15 billion, compared to the consensus revenue estimate of $$1.13 billion.

What price target have analysts set for RDNT?

2 brokerages have issued twelve-month price targets for RadNet's stock. Their forecasts range from $17.50 to $23.00. On average, they anticipate RadNet's share price to reach $20.25 in the next year. This suggests that the stock has a possible downside of 5.4%. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.

Has RadNet been receiving favorable news coverage?

Headlines about RDNT stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RadNet earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for RadNet.

Are investors shorting RadNet?

RadNet saw a drop in short interest in December. As of December 31st, there was short interest totalling 1,420,000 shares, a drop of 10.1% from the December 15th total of 1,580,000 shares. Based on an average daily trading volume, of 480,600 shares, the short-interest ratio is presently 3.0 days. Approximately 3.4% of the shares of the stock are short sold. View RadNet's Current Options Chain.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL), AbbVie (ABBV), AT&T (T), UnitedHealth Group (UNH), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), NovaBay Pharmaceuticals (NBY), Athersys (ATHX) and Baidu (BIDU).

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (1.68%), State of Alaska Department of Revenue (0.06%), Assenagon Asset Management S.A. (0.05%), Wedge Capital Management L L P NC (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A. and Wedge Capital Management L L P NC. Company insiders that have sold RadNet company stock in the last year include David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Louisiana State Employees Retirement System. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $21.41.

How big of a company is RadNet?

RadNet has a market capitalization of $1.08 billion and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.View Additional Information About RadNet.

What is RadNet's official website?

The official website for RadNet is http://www.radnet.com/.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel